SCHEMBL3105476

SCHEMBL3105476

CC(O)(CC(=O)CCc1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
KEAP1 Q14145 1/20 0.48
KMT2A Q03164 2/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
FFAR1 O14842 1/20 0.46
TRPA1 O75762 1/20 0.45
CYP2C19 P33261 2/20 0.44
HIF1A Q16665 1/20 0.44
ALOX5 P09917 1/20 0.44
HDAC2 Q92769 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
MMP12 P39900 1/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC3 O15379 1/20 0.42
MAPK1 P28482 1/20 0.42
ADRA1A P35348 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086629 0.91 TRPV1 (0.49) ALDH1A1L3MBTL1TDP1FFAR1ALOX5
SCHEMBL3093133 0.90 HDAC1 (0.51) ALDH1A1TDP1CYP2C19HIF1AALOX5
SCHEMBL30944447 0.84 CYP2C19 (0.55) ALDH1A1L3MBTL1KMT2AHTTCYP2C19
SCHEMBL8242742 0.82 ALDH1A1 (0.57) ALDH1A1L3MBTL1TDP1KEAP1KMT2A
SCHEMBL3094319 0.82 TRPV1 (0.48) ALDH1A1HDAC2HDAC8HDAC6HDAC1
SCHEMBL20927213 0.80 ALDH1A1 (0.50) ALDH1A1L3MBTL1TDP1KEAP1KMT2A
SCHEMBL23369879 0.78 ALDH1A1 (0.52) ALDH1A1L3MBTL1TDP1KEAP1KMT2A
Hydrochloric Acid SCHEMBL8153499 0.78 ALDH1A1 (0.52) ALDH1A1L3MBTL1TDP1KEAP1KMT2A
SCHEMBL1202058 0.78 CYP2C19 (0.69) ALDH1A1L3MBTL1KMT2AHTTCYP2C19
SCHEMBL25332888 0.78 CYP2C19 (0.69) ALDH1A1L3MBTL1KMT2AHTTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA 2010-09-30 US disclosed
EP-2227449-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY Pulkkinen, Juha (FI) 2010-09-15 EP disclosed
WO-2009066008-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY PULKKINEN JUHA (FI) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249243-A1 NOVEL BETA-HYDROXYKETONES AND BETA-ALKOXYKETONES WITH ESTROGENIC ACTIVITY HSD17B11, HSD17B7, CYP19A1 ALDH1A1 577/4885L3MBTL1 4833/4885TDP1 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.